Atossa Therapeutics, Inc. (ATOS:NASDAQ) closed at $2.91 on October 16, 2026, up 9.81% on the day. The stock trades 81.2% below its 52-week high of $15.45 and 71.2% above its 52-week low of $1.70. Over the past year, it lost 80.2%. Atossa Therapeutics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| +21.82% | +21.25% | +16.87% | -52.84% | -80.20% |
In 252 trading sessions since October 16, 2025, ATOS closed higher on 107 days (42%). Its best day was October 1, 2026 (+16.41%) and its worst was June 11, 2026 (-41.14%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 1 time.
Atossa Genetics Inc., a clinical-stage pharmaceutical company, focuses on developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions in the United States. The company is conducting a Phase II clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in-situ and breast cancer; and a pharmaceutical program under development is Afimoxifene Topical Gel for the treatment and prevention of hyperplasia of the breast. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Find more stocks like ATOS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.